Dataset opportunity
Phenox — 医疗影像数据集机会
由 Phenox 持有的中等规模医疗影像数据集，可用于诊断人工智能和计算机视觉。
Score
61.6
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球医疗影像人工智能市场 = 2025 年为 21 亿美元，复合年增长率为 23.9%。
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- 🧑💻Hiring a data role
招聘高级临床项目经理以实现研究里程碑交付
source ↗
Profile
Dataset profile
Type
医疗影像数据集
Modality
影像
Sector
医疗保健
Volume
中等
Freshness
定期
Rarity
高（专有）
Accessibility
受限
Legal
公司所有 — GDPR 敏感（个人身份信息审查）
Buyer persona
医疗人工智能和诊断影像公司
Phenox 持有一个重要的医疗影像数据集，包含来自其临床研究和业务运营的各种影像模态。这些病历记录和专有影像的集合经过精心整理，可直接用于开发和验证高性能诊断人工智能算法，其主要价值在于与真实患者结果的直接联系。
全球医疗影像人工智能市场在 2025 年的估值为21 亿美元，预计将以23.9% 的复合年增长率扩张，显示出巨大的增长和需求。[8] 虽然访问受到严格的 GDPR、临床试验法规的约束，并且需要 Wallaby Medical 的集团层面批准，但该数据的稀缺性和临床相关性使其成为寻求在该快速增长市场中获得竞争优势的人工智能开发者的宝贵资产。⚠ 尽职调查（有价值的数据，可协商访问）：医疗数据受严格的 GDPR 和临床试验监管合规性约束；Wallaby Medical 的子公司；需要集团层面的数据治理批准；数据访问受临床研究特定患者同意书的限制 · 公司：收购了 Wallaby Medical。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
证据证实 Phenox 拥有一个专有数据集，涵盖了使用其专业医疗设备治疗动脉瘤的20,000 多名患者。这些高容量的真实世界数据，包括临床试验结果和血管造影随访，是开发和验证下一代诊断人工智能模型的关键资产。对于医疗人工智能公司而言，该数据集提供了一个难得的机会，可以在大量特定患者群体上训练算法，从而加速进入预计到 2025 年将达到 21 亿美元的快速增长的医疗影像人工智能市场。
See dimension details ↓- Dataset Specificity78
占主导地位的“病历记录”，医疗保健行业，2 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity70
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
定期
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
适用于诊断人工智能
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
高买家需求源于医疗影像人工智能市场的快速扩张，该市场正以 23.9% 的复合年增长率增长，对高质量、经过临床验证的培训数据产生了强烈需求。[8]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
个人身份信息/受监管
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
高难度，收购了 Wallaby Medical
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 种证据类型，3 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
所有权=公司所有，许可=GDPR 敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence45
收购了 Wallaby Medical
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation39
1 个数据需求信号（1 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit92
✓ 良好目标 — Phenox 是一个良好目标，因为它开发和制造神经血管医疗器械，由此产生的影像数据是其核心业务运营的副产品，而不是其主要销售产品。问题：该公司于 2022 年被 Wallaby Medical 收购，成为一个更大组织的一部分，这可能会使决策过程复杂化。[1, 5, 17]
- Deep Qualification90
⚠ 需要审查 — Phenox 是一家医疗器械制造商，其临床试验产生了一个有价值的专有医疗影像数据集；然而，访问受到 GDPR、临床试验法规和患者同意的严格限制。[许可受限]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
该证据指向来自随机临床试验的结构化数据集，提供了高质量的纵向患者结果，这对于训练预测性诊断模型至关重要。
Image collection
该集合包括来自多中心研究的血管造影随访影像（DSA），提供了用于改进动脉瘤治疗分析的计算机视觉算法所需的特定医疗影像数据。
business_records
这些记录证实了一个大规模的全球数据集，涵盖了20,000 多名患者，表明了大量对构建强大且可推广的人工智能应用高度渴求的真实世界证据。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Phenox Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging market = $2.1 billion in 2025, CAGR 23.9% (source: Global Market Insights). [8]. Investment score 61.6/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Probot — 工业传感器数据集机会
View opportunity →工业Zenergyic — 维护日志数据集机会
View opportunity →移动Paack — 移动遥测数据集机会
View opportunity →